Top Qs
Timeline
Chat
Perspective

Tactogen

American pharmaceutical company From Wikipedia, the free encyclopedia

Tactogen
Remove ads

Tactogen is a public benefit corporation and start-up pharmaceutical company based in Palo Alto, California that is developing novel MDMA-like entactogens and psychedelics as medicines.[1][2][3][4][5][6][7][8] Its stated goal is to develop new MDMA-like drugs with improved effectiveness, tolerability, and safety, as well as gentleness and accessibility, for treatment of psychiatric disorders and other conditions.[1][2][5][7] Tactogen was co-founded by neuroscientist Matthew J. Baggott and Luke Pustejovsky in 2020.[1][6][8] Baggott is the chief executive officer (CEO) while Pustejovsky is the chief operating officer (COO).[6][9]

Quick Facts Company type, Industry ...
Remove ads

Drug candidates

Summarize
Perspective

Tactogen has patented various novel entactogen-like compounds from different chemical families.[2][10][11][9] These include benzofurans like 5-MAPB, 5-MBPB, and BK-5-MAPB,[12][13][14][15] benzothiophenes like 5-MAPBT,[16][15] α-alkyltryptamines like BK-NM-AMT and BK-5F-NM-AMT,[17][18] indolizines like 2ZEDMA, 1ZP2MA, and Z2MAP1O,[19][20] 2-aminoindanes like "BFAI",[21] and non-racemic mixtures of enantiomers.[17][12][22] It also has several drugs in its developmental pipeline, including TACT411, TACT833, TACT908, and TACT523.[1][7][23][24] The company is said to have been the first to develop novel entactogens.[9] It says that it has synthesized hundreds of different molecules[9] and claims that it has developed the largest known library of entactogenic compounds.[11]

At least some of Tactogen's candidates are said to be benzofurans, for instance 5-MAPB.[1] In preliminary research, they have found that 5-MAPB appears to reduce social anxiety and promote self-compassion similarly to MDMA, but does not seem to promote energy and positive emotions as much as MDMA, and hence may retain therapeutic efficacy with less misuse potential.[1] Phase 1 and 2 clinical trials of Tactogen's drug candidates in healthy volunteers and people with post-traumatic stress disorder (PTSD) are said to be in the planning stages as of February 2024.[1] Some of its candidates have been said to lack the serotonergic neurotoxicity of MDMA in animals.[1]

Tactogen is additionally studying a combination of MDMA and citalopram wherein MDMA is followed by the selective serotonin reuptake inhibitor (SSRI) citalopram in efforts to reduce the serotonergic neurotoxicity and negative after-effects of MDMA.[7][25][23][26] A phase 2 trial of this strategy is planned to commence in 2025.[7][25][23] Following the Food and Drug Administration (FDA)'s rejection of Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD), Tactogen said in late 2024 that it is seriously considering prioritizing its novel compounds over its MDMA/citalopram product.[7]

Remove ads

Funding

In January 2023, it was reported that Tactogen had raised $6.3 million since early 2020.[9][27]

Selected publications

Presentations

  • Matthew Baggott (18 June 2023). "Better Than Ecstasy: Progress in Developing a Novel Class of Therapeutic with Matthew Baggott, PhD". YouTube. Tactogen. Retrieved 20 November 2024.
  • Baggott M (23 June 2023). Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine. PS2023 [Psychedelic Science 2023, June 19–23, 2023, Denver, Colorado]. Denver, CO: Multidisciplinary Association for Psychedelic Studies.

Studies

See also

References

External links

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads
Remove ads